Sarji K E, Stratton R D, Wagner R H, Brinkhous K M
Proc Natl Acad Sci U S A. 1974 Aug;71(8):2937-41. doi: 10.1073/pnas.71.8.2937.
Platelet-active "von Willebrand factor" is a poorly characterized activity of a plasma-protein macromolecular complex. A new simple assay for von Willebrand factor is based on the dose response relation of the factor and the ristocetin platelet aggregation time. This assay uses the "snowstorm" macroscopic endpoint. A multiply transfused subject with von Willebrand's disease was observed to have a circulating inhibitor that blocks normal ristocetin aggregation of platelets, but not ADP-, epinephrine-, or collagen-induced aggregation. The inhibitor was not adsorbed by normal platelets, and was stable to heating at 56 degrees for 30 min and to repeated freezings and thawings. This inhibitor also prevents action on human platelets by platelet-aggregating factor of bovine plasma, indicating this bovine factor activity is a function of von Willebrand factor. Three inhibitors were compared: (1) the von Willebrand factor inhibitor specifically blocked von Willebrand factor activity, (2) a human antibody from a hemophiliac inhibited only antihemophilic factor activity, and (3) a rabbit antiserum to a preparation of human antihemophilic factor inhibited both activities. The active site for von Willebrand factor on the macromolecular complex appears to be spaced some distance from the antihemophilic factor site.
血小板活性“血管性血友病因子”是血浆蛋白大分子复合物中一种特性尚不明确的活性物质。一种新的简单的血管性血友病因子检测方法基于该因子与瑞斯托霉素诱导血小板聚集时间的剂量反应关系。此检测采用“暴风雪”宏观终点。观察到一名多次输血的血管性血友病患者体内存在一种循环抑制剂,它能阻断血小板正常的瑞斯托霉素诱导聚集,但不影响二磷酸腺苷(ADP)、肾上腺素或胶原诱导的聚集。该抑制剂不被正常血小板吸附,在56摄氏度加热30分钟以及反复冻融后仍保持稳定。这种抑制剂还能阻止牛血浆中的血小板聚集因子对人血小板的作用,表明这种牛因子的活性是血管性血友病因子的一种功能。比较了三种抑制剂:(1)血管性血友病因子抑制剂特异性地阻断血管性血友病因子活性;(2)一名血友病患者的人源抗体仅抑制抗血友病因子活性;(3)针对人抗血友病因子制剂的兔抗血清抑制两种活性。大分子复合物上血管性血友病因子的活性位点似乎与抗血友病因子位点相隔一定距离。